Electronic Supplementary Material (ESI) for Journal of Materials Chemistry B.

ELECTRONIC SUPPLEMENTARY INFORMATION

L-Dopa release from mesoporous silica nanoparticles engineered through the concept of drug-structure-directing agents for Parkinson's disease

V. Morales[a], J. McConnell[b], M. Pérez-Garnes[a], N. Almendro[a], R. Sanz[a] and R.A. García-Muñoz[a,*]

[a]Department of Chemical and Environmental Technology, Rey Juan Carlos University, C/ Tulipán s/n, 28933, Móstoles, Madrid, Spain

[b]Department of Chemical & Process Engineering. University of Strathclyde, Glasgow G1 1XJ, UK

*E-mail: rafael.garcia@urjc.es

Keywords: mesoporous silica nanoparticles, Parkinson disease, drug delivery systems, long-term pharmacokinetic release, drug-structure directing agent (DSDA).



Figure S 1. FITR spectrum of DSDAs and HMSNs: A) NOLD as surfactant and different concentration of reagents in the medium of synthesis, B) NDLD as surfactant and different concentration of reagents in the medium of synthesis, and C) NDLD as surfactant and different pH of the medium of synthesis. Insets represent magnification of wavenumbers between 4.000 and 1.500 cm^{-1}.



Figure S2. 1H and 13C NMR liquid state spectrum of N-decanoyl-L-dopa (NDLD).



Figure S3. 1H and 13C NMR liquid state of N-oleoyl-L-dopa (NOLD).



Figure S4. TEM images of HMSNs synthetized using NOLD as surfactant and at different pH: HMSN18-B at pH 8.5 (A-B), HMSN18_C at pH 9 (C-D) and HMSN18-D at pH 9.5 (E-F).